penKid

About SphingoTec

SphingoTec is a privately-held diagnostics company specializing in the development and out-licensing of novel biomarkers for critical care. Its core strategy involves advancing proprietary biomarkers to the commercial stage and forming partnerships with established in-vitro diagnostic (IVD) companies for global distribution. The company's lead biomarkers, penKid for acute kidney injury assessment and bio-ADM for sepsis and endothelial dysfunction, target significant unmet needs in hospital emergency and intensive care settings. Recent clinical validation and a new product launch with partner Boditech Med demonstrate progress in translating its pipeline into clinical tools.

Therapeutic Areas